Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

A legfontosabb adatok

Ki végzi
Sanofi
Hol
Buffalo és El Paso (Egyesült Államok)Mind a 2 helyszín megnézéseMég 6 másik országban, 33 helyszínen
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
22 fő vett részt
Kezdés
2022. jún. 1.
Befejezés
2024. nov. 20.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Tusamitamab ravtansine
A regiszteradat frissítve
2025. augusztus 29.
Miért állt le
Sponsor decision, the decision is not related to any safety concern.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Histologically or cytologically proven diagnosis of NSQ NSCLC metastatic disease at study entry; progression after platinum-based chemotherapy and immune checkpoint inhibitor
  • Participants with moderate or negative CEACAM5 expression as demonstrated prospectively by central laboratory via immune histochemistry (ICH) and high circulating CEA levels (≥100 ng/mL). Moderate CEACAM5 expression is defined as intensity ≥ 2 + in ≥ 1% and <50 % of tumor cells. Negative CEACAM5 expression is defined as intensity of 1 + whatever the percentage of stained tumor cells or <1% of tumor cells
  • At least one measurable lesion by RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Women of childbearing potential or male patient with women of childbearing potential who agree to use highly effective method of birth control

Ki nem vehet részt

  • Significant concomitant illness that could impair the participation in the study or interpretation of the results or any major surgery with 3 weeks prior treatment administration
  • Nonresolution of any prior treatment-related toxicity to <Grade 2 according to NCI CTCAE v5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy
  • Previous history of and/or unresolved corneal disorders. The use of contact lenses is not permitted
  • Prior treatment with maytansinoid derivatives (DM1 or DM4 antibody drug conjugate) or any drug targeting CEACAM5
  • Concurrent treatment with any other anticancer therapy
  • Patients with untreated brain metastases or history of leptomeningeal disease
  • History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment
  • History of known uncontrolled infection with human immunodeficiency virus (HIV), or unresolved viral hepatitis
  • Poor bone marrow, liver or kidney functions; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Helyszínek itt: Egyesült Államok

Még 6 másik országban, 33 helyszínen

  • Roswell Park Cancer Institute Site Number : 8400004Buffalo, Egyesült Államok
  • El Paso, TexasHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous non-small-cell-lung-cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 expression tumors and high circulating carcinoembryonic antigen (CEA).

A teljes eredeti leírásKevesebb

Participants who will be enrolled, will receive tusamitamab ravtansine as monotherapy every two weeks (Q2W) until disease progression, unacceptable adverse event (AE), initiation of a new anticancer therapy, or the participant's or investigator's decision to stop the treatment, whichever comes first. A total of approximately 38 participants are planned to be treated.

A vizsgálat csoportja

  • Tusamitamab ravtansineA vizsgált kezelés

    Tusamitamab ravtansine dose will be administered on Day 1 via IV infusion and repeated once every 2 weeks. The duration of 1 cycle will be 14 days (1 administration of tusamitamab ravtansine per cycle).

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
A regiszteradat frissítve
2025. augusztus 29.